SAB Biotherapeutics EBIT

SAB Biotherapeutics (SABS) currently reports a EBIT of $-130M as of June 2026. That compares with $-36M in the prior-year period — down 271.5% year over year. That is below the sector sector average of $-9.6M. Use the charts on this page to explore SAB Biotherapeutics's EBIT history and peer comparisons.

SAB Biotherapeutics's EBIT decreased from $-36M to $-130M — a 271.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SAB Biotherapeutics's EBIT of $-130M is lower than the its sector sector average of $-9.6M. That is roughly 1295.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

SAB Biotherapeutics reported $-130M in EBIT as of June 2026. That compares with $-36M in the prior-year period — down 271.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-130M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-9.6M. From there, open related valuation or income-statement pages for SAB Biotherapeutics, and consider following SABS for alerts when major investors trade the stock.